
    
      This is a multicenter, double-blinded, randomized, placebo-controlled clinical trial to
      investigate the efficacy and safety of berberine on subjects with Non-alcoholic
      Steatohepatitis.Patients with biopsy-proven non-alcoholic steatohepatitis (NASH) from 18-65
      years of age were enrolled. Patients should had no excessive alcohol intake or use of any
      hepatoprotective or hepatotoxicity medication within 3 months before enrollment.Patients will
      have an screening period 12 weeks, and a 48-week double-blinded treatment period.
    
  